Bend Research is expanding into biotherapeutics, offering new technologies and equipment aimed at improving biotherapeutic and vaccine production. Bend Research will partner with clients to develop and optimize pharmaceutical engineering processes and technologies by combining fundamental cellular processes with the optimal cell environment for each production phase.

“The campaign is grounded in science and engineering fundamentals, with a focus on applying macro engineering approaches to leverage an understanding of complex cell-biology,” said Dr. Lisa Graham, senior vice president at Bend Research. “We’ve validated this approach in our small-molecules business and we’re now uniquely positioned to bring this valuable experience to the broader biotherapeutics market.”

As part of a long-term collaboration with Pfizer, both companies worked on a joint campaign to design a plant aimed at reducing the capital investment required for new biotherapeutics production facilities by half, and reducing conventional plant operating costs by two-thirds.

According to John Ludwig, vice president in BioTherapeutics Pharmaceutical Sciences for Pfizer Worldwide R&D, “Pfizer’s partnership with Bend Research has focused on developing innovative new technologies in bioprocessing and integrated process analytics. We are pleased these technologies are supporting advancement of our biotherapeutics and vaccines portfolio.”